CCMs are relatively common vascular malformations that arise predominantly in the central nervous system, causing haemorrhagic stroke and seizure 1 . CCMs arise from loss of function mutations in three genes, KRIT1, CCM2 and PDCD10, that encode components of a heterotrimeric, intracellular adaptor protein complex (the 'CCM complex') 2, 3 . The clinical course of familial CCM disease is highly variable, even among individuals who share identical germline mutations [4] [5] [6] , suggesting the existence of powerful genetic and/or environmental disease modifiers. Present treatment for CCMs consists solely of palliative therapies or neurosurgical resection.
Previous studies of vertebrate genetic models and human CCM lesions have demonstrated that loss of the CCM complex results in vascular lesion formation owing to increased MEKK3-KLF2/4 signalling in brain endothelial cells [7] [8] [9] [10] , and that the CCM complex suppresses MEKK3-KLF2/4 signalling through a direct interaction between CCM2 and MEKK3 (refs 11, 12) . As there is a lack of effective drugs that target the MEKK3-KLF2/4 pathway, these molecular insights have not been immediately translational. However, they raise a key mechanistic question: if the role of the CCM complex is to negatively regulate MEKK3-KLF2/4 signalling, what activates this pathway in brain endothelial cells? Identification of upstream activators of this pathway is needed to understand the pathogenesis of CCM disease and reveal viable therapeutic strategies.
CCM formation is driven by GNB and LPS
To investigate CCM formation in mice, we generated animals in which endothelial-specific deletion of Krit1 or Ccm2 was induced one day after birth (P1, iECre;Krit1 fl/fl and iECre;Ccm2 fl/fl ; hereafter denoted as Krit1 ECKO and Ccm2 ECKO , respectively). In this model, vascular malformations first appear in the cerebellar white matter at P6, with numerous mature lesions present by P10 (refs 9, 13) . These mice were maintained as inbred breeding colonies and initially demonstrated a highly penetrant lesion phenotype (termed 'susceptible'; Fig. 1a, top) . However, following a change in vivarium at the University of Pennsylvania, we noted the spontaneous emergence of Krit1 ECKO and Ccm2 ECKO subcolonies that developed barely visible hindbrain lesions at P17 (termed 'resistant'; Fig. 1a, bottom) . Previous studies have demonstrated 100% CCM penetrance on a C57BL/6J background 13 , but Ccm2 ECKO animals backcrossed seven generations to C57BL/6J remained resistant to CCM formation (Extended Data Fig. 1a) . Importantly, among a large population of CCM-resistant animals, we detected a small number of individual pups that exhibited robust CCM formation in association with the presence of intra-abdominal, Gram-negative bacterial (GNB) abscesses that probably developed following tamoxifen injection (Fig. 1b, c, Extended Data Fig. 1b ). This observation suggested that Gram-negative infection accelerates CCM pathogenesis.
To directly assess the role of Gram-negative infection, Gramnegative abscesses were induced in resistant Ccm2 ECKO mice at P5 by intra-peritoneal injection of live Bacteroides fragilis. Following B. fragilis injection, 9 out of 16 resistant Ccm2 ECKO animals developed large CCM lesions (termed 'responders'; Fig. 1d , left), but 7 out of 16 animals did not (termed 'non-responders'; Fig. 1d , right). Responders to B. fragilis injection exhibited splenic abscesses and higher spleen weights compared with non-responders (Fig. 1e, f) , suggesting that Cerebral cavernous malformations (CCMs) are a cause of stroke and seizure for which no effective medical therapies yet exist. CCMs arise from the loss of an adaptor complex that negatively regulates MEKK3-KLF2/4 signalling in brain endothelial cells, but upstream activators of this disease pathway have yet to be identified. Here we identify endothelial Toll-like receptor 4 (TLR4) and the gut microbiome as critical stimulants of CCM formation. Activation of TLR4 by Gram-negative bacteria or lipopolysaccharide accelerates CCM formation, and genetic or pharmacologic blockade of TLR4 signalling prevents CCM formation in mice. Polymorphisms that increase expression of the TLR4 gene or the gene encoding its co-receptor CD14 are associated with higher CCM lesion burden in humans. Germ-free mice are protected from CCM formation, and a single course of antibiotics permanently alters CCM susceptibility in mice. These studies identify unexpected roles for the microbiome and innate immune signalling in the pathogenesis of a cerebrovascular disease, as well as strategies for its treatment.
haematogenous spread of GNB from the site of the abscess was required to stimulate CCM formation in resistant Ccm2 ECKO animals. As GNB stimulate mammalian cellular responses largely through cellmembrane-derived lipopolysaccharide (LPS), we tested the sufficiency of LPS to drive CCM formation. Injection of LPS resulted in the formation of large lesions in resistant Ccm2 ECKO animals ( Fig. 1g-i ), but had no effect on Ccm2 fl/fl littermates (Extended Data Fig. 1c, d ). These findings reveal that blood-borne GNB and LPS are strong drivers of CCM formation in mice.
Endothelial TLR4 drives CCM lesion formation
We previously demonstrated that loss of the CCM proteins KRIT1 or CCM2 results in vascular malformation owing to increased MEKK3 signalling in endothelial cells 9 . LPS activates intracellular signals through the innate immune receptor TLR4 (ref. 14) , and MEKK3-deficient fibroblasts are unable to activate downstream signalling responses to LPS in vitro 15 . We therefore hypothesized that GNB and LPS accelerate CCM formation by activating TLR4-MEKK3-KLF2/4 signalling in CCM-complex-deficient brain endothelial cells. Analysis of susceptible Krit1 ECKO mice revealed that CCM lesions arise in the absence of an immune-cell infiltrate at P6 (Extended Data Fig. 2 ), and that a single dose of LPS at P5 accelerated CCM formation by P6 (Fig. 2a) . Consistent with a mechanism that is intrinsic to brain endothelial cells, we observed synergistic effects of CCM-complexdeficiency and LPS injection on the expression of CCM-driving genes Klf2 and Klf4, known endothelial TLR4 signalling targets IL-1β (Il1b) and E-selectin (Sele), as well as on the level of phospho-myosin light chain (Fig. 2b, Extended Data Fig. 1e ).
To directly assess the requirement for endothelial TLR4 in spontaneous CCM formation, we bred iECre;Krit1 
Tlr4
fl/fl mice using animals from the susceptible Krit1 ECKO colony. Loss of a single endothelial Tlr4 allele resulted in an approximately 75% reduction in CCM lesion burden at P10, whereas loss of both resulted in virtually complete prevention of CCM lesion formation (Fig. 2c, d , Extended Data Fig. 3a ). Cd14 encodes a soluble TLR4 co-receptor that binds LPS and facilitates TLR4 signalling 16, 17 . Although less complete, global loss of CD14 also prevented CCM formation in susceptible Krit1 ECKO mice (Fig. 2e , f, Extended Data Fig. 3b ). Lineage tracing studies confirmed that Cdh5(PAC)-Cre ERT2 transgene activity was restricted to endothelial cells (Extended Data Fig. 4 ECKO littermates without (top) and with (bottom) spontaneous abdominal Gram-negative abscess. Arrows, CCM lesions; scale bars, 1 mm. c, The bacterial abscess ('absc') identified in b contains GNB (arrows). Scale bars, 4 mm (top) and 10 μ m (bottom).
d, CCM formation in resistant Ccm2
ECKO littermates following injection with a live B. fragilis/autoclaved caecal contents mixture (B. fragilis) or autoclaved caecal contents (ACC) alone (ACC vehicle). Scale bars, 1 mm. e, f, Resistant Ccm2 ECKO responders exhibit splenic abscesses and increased spleen weight compared with non-responders. g, CCM formation in resistant Ccm2 ECKO mice following vehicle or LPS treatment. Scale bars, 1 mm. h, i, Quantification of lesion and total brain volumes. Error bars shown as s.e.m. and significance determined by one-way ANOVA with Holm-Sidak correction for multiple comparisons or unpaired, two-tailed t-test. * * * * P < 0.0001; * * * P < 0.001; NS, P > 0.05. 
Krit1
fl/fl animals developed CCM lesions like those in Krit1 ECKO animals (Extended Data Fig. 5b, c) . These genetic findings identify endothelial TLR4 signalling as a critical driver of CCM formation in mice.
TLR4/CD14 expression parallels human CCM burden
Studies in humans and mice have demonstrated that TLR4 signalling positively correlates with receptor expression levels 19, 20 , suggesting that polymorphisms associated with changes in TLR4 expression might influence the progression of human CCM disease. We recently analysed 830 genetic variants of 56 inflammatory and immune related genes in 188 patients with an identical nonsense mutation in the KRIT1 gene (Q455X) in whom CCM lesion burden was measured using magnetic resonance imaging (MRI) 6 . Following statistical analysis, single-nucleotide polymorphisms (SNPs) in only two genes, TLR4 (rs10759930, chromosome 9; Fig. 3a) and CD14 (rs778587, chromosome 5; Fig. 3a) , were found to be significantly associated with increased CCM lesion number. Further analysis of genes in TLR4-MEKK3-KLF2/4 signalling pathways identified additional SNPs for TLR4 (rs10759931) and CD14 (rs778588) in linkage disequilibrium with those previously identified (Fig. 3a) , but none in other pathway genes (see Methods) that associated with altered lesion burden.
Notably, the TLR4 and CD14 SNPs associated with increased CCM lesion number are in the 5′ genomic region of each gene (Fig. 3a) , and constitute cis expression quantitative trait loci (cis-eQTLs) that positively regulate whole-blood-cell expression of TLR4 and CD14 in a dose-dependent manner corresponding with risk allele number 21, 22 ( Fig. 3b, c) . These results were independently corroborated by a similar GTEx Consortium study (see Methods). MRI analysis revealed additive CCM lesion numbers in patients with the KRIT1(Q455X) mutation who carried one, two or three TLR4 or CD14 risk alleles (Fig. 3d-f) . Carriers of TLR4 or CD14 risk alleles were associated with 72% or 49% more lesions compared to non-carriers, respectively (Fig. 3e, f ). These findings demonstrate that genetic changes associated with altered TLR4 and CD14 expression result in coordinate changes in CCM lesion formation in both humans and mice (Fig. 2c-f) , supporting the hypothesis that TLR4 and/or CD14 signalling plays a central and conserved role in CCM pathogenesis.
Bacteria drive CCM formation in mice
Although endogenous TLR4 ligands have been identified 23 , the best-characterized TLR4 ligand is GNB-derived LPS 14, 24 . The findings that CCM pathogenesis requires endothelial TLR4 and CD14 ( Fig. 2c-f) , and that CCM susceptibility shifted markedly with a change in vivarium (Fig. 1a) , suggested that GNB in the microbiome may be a primary source of TLR4 ligand and an important regulator of CCM disease. To directly assess the role of the bacterial microbiome during CCM formation, we delivered susceptible E19.5 Krit1 ECKO neonates using sterile caesarean section (C-section) and fostered them to imported conventional or germ-free Swiss Webster mothers (Fig. 4a) . All fostered Krit1 ECKO neonates exhibited robust CCM formation at P10 when raised by conventional Swiss Webster mothers (Fig. 4b, c, Extended Data Fig. 3c ). In contrast, 7 out of 8 fostered Krit1
ECKO neonates raised in germ-free conditions failed to develop CCM lesions, indicating that bacteria are required for CCM pathogenesis in most animals (Fig. 4b, c Fig. 3c ). Previous studies have demonstrated that MEKK3 is required for signalling downstream of cytokines IL-1β 15 and TNFα 25 , and other pattern-recognition receptors can signal in endothelial cells through the same effectors used by TLR4 (refs 26, 27) . Thus, the generation of lesions in a germ-free Krit1 ECKO neonate suggested that cytokines or immune receptors other than TLR4 may also drive CCM formation in vivo. To directly test the ability of non-TLR4 ligands to stimulate CCM formation, we administered IL-1β , TNFα , the TLR3 ligand polyinosinic:polycytidylic acid (polyI:C), and the TLR2 ligand peptidoglycan to resistant Ccm2 ECKO neonates and assessed the effects on CCM formation. IL-1β and poly(I:C) treatment significantly increased CCM lesion volume, although no difference was observed with TNFα or peptidoglycan (Extended Data Fig. 6 ). These findings identify the bacterial biome as a critical driver of CCM formation in vivo, but also demonstrate that cytokines and innate immune ligands other than LPS can support CCM formation in vivo.
CCM susceptibility is associated with gut GNB

Assessment of CCM formation in Krit1
ECKO and Ccm2 ECKO mice at P10 revealed a remarkably binary phenotype in which susceptible mice developed numerous lesions, whereas resistant mice developed virtually none (Fig. 5a , b, d, e). Lesion volumes were indistinguishable among susceptible Krit1 ECKO and Ccm2 ECKO animals and no difference in brain endothelial Tlr4 expression was detected between susceptible and resistant animals (Extended Data Fig. 1f ), indicating that non-genetic factors such as the gut microbiome have a role in determining CCM susceptibility.
To identify specific bacteria that associate with CCM susceptibility or resistance, we performed 16S rRNA gene sequencing of bacterial Error bars shown as 95% confidence intervals and significance determined by one-way ANOVA with Holm-Sidak correction for multiple comparisons. * * * * P < 0.0001; * * * P < 0.001; * * P < 0.01; * P < 0.05. DNA extracted from the faeces of female mice that raised susceptible or resistant Krit1 ECKO and Ccm2 ECKO animals (Extended Data Fig. 7a ). A PERMANOVA test of unweighted UniFrac distances (a measure of difference between biological groups) revealed clear separation of susceptible and resistant bacterial microbiome communities, regardless of whether they were derived from Krit1 ECKO or Ccm2 ECKO colonies (P < 0.0001, R 2 = 0.051; Fig. 5f ). Further accounting for relative abundances of bacterial species, significant separation between susceptible and resistant animals was also observed using weighted UniFrac analysis (P = 0.0016, R 2 = 0.091; Fig. 5g ). Fitting generalized, linear mixed-effects models for commonly present bacterial taxa identified one major group that differed significantly between the gut biomes of susceptible and resistant animals: Gram-negative Bacteroidetes family s24-7 (denoted as s24-7) was significantly more abundant in susceptible animals irrespective of genotype (Fig. 5h , Extended Data Fig. 7b, c) . Notably, 16S sequencing of gut bacteria from conventional Swiss Webster foster mothers revealed high levels of s24-7, explaining susceptibility to CCM formation by C-section/fostered Krit1 ECKO neonates (Figs 4, 5c-e, h). These findings support a key role for the gut microbiome in CCM disease pathogenesis, and suggest that CCM susceptibility can be significantly affected by levels of specific GNB in the gut microbiome.
TLR4 block or altering the microbiome prevents CCM
Our studies do not exclude a role for TLR4 signalling in non-brain endothelial cells. However, they are most consistent with a disease model in which brain endothelial TLR4 and/or CD14 receptors stimulate MEKK3-KLF2/4 signalling in response to GNB or GNBderived LPS that translocate from the gut lumen to circulating blood ( Fig. 6a )-a process strongly influenced by the composition of the gut microbiome [28] [29] [30] [31] . This model predicts two novel approaches to treat CCM disease: TLR4 blockade and manipulation of the microbiome.
TAK-242 (resatorvid) is a small-molecule TLR4 antagonist that binds the intracellular domain of TLR4 and blocks signal transduction 32 .
Treatment of susceptible Krit1
ECKO mice with TAK-242 demonstrated an approximately 80% reduction in CCM lesion volume (Fig. 6b-d) .
LPS-RS is a hypo-acetylated LPS derived from Rhodobacter sphaeroides that competitively antagonizes TLR4 (ref. 33). Treatment of susceptible Krit1
ECKO mice with LPS-RS conferred a greater than 90% reduction in CCM lesion volume (Extended Data Fig. 8 ). These studies confirm the essential role of TLR4 signalling in CCM pathogenesis and suggest that TLR4 antagonists may be effective therapies.
To test the effect of deliberate microbiome manipulation on CCM formation, we designed an intergenerational study using a single course of antibiotics to reset the microbiome (Fig. 6e) . Male-female pairs of susceptible Krit1 ECKO mice were crossed and baseline CCM formation was measured in the offspring at P10 (Fig. 6f ; 'generation 1, ABX-naive'). Next, the same male-female pairs were mated a second time and broad-spectrum antibiotics were administered maternally from E14.5 to P10 before lesion assessment ( Fig. 6g ; 'generation 2, maternal ABX'). Finally, 4-6 weeks after withdrawal of antibiotics, the same male-female pair delivered a third litter and lesions were assessed at P10 ( Fig. 6h ; 'generation 3, post-ABX'). As expected, generation 1 susceptible Krit1 ECKO mice developed numerous lesions (Fig. 6f , i, Extended Data Fig. 3d ). Consistent with our findings using germ-free animals, generation 2 maternal antibiotic treatment reduced CCM formation by > 95% (Fig. 6g, i) , in association with a 96% reduction in total gut bacterial load (Fig. 6j) . Remarkably, generation 3 Krit1
ECKO offspring from the same mating pair failed to develop CCMs (Fig. 6h, i) , despite bacterial load returning to pre-antibiotic levels (Fig. 6j) , except for a single generation 3 animal that developed an intra-abdominal abscess with pronounced splenomegaly (Fig. 6i, red star, Extended Data Fig.  9a ). Maternal treatment with vancomycin alone, a broad-spectrum antibiotic specific for Gram-positive bacteria, had no effect on CCM formation, consistent with a causal role for GNB (Extended Data Fig. 9b-h) . Measurement of s24-7 levels in the intestines of generation 1, 2 and 3 neonates collected for analysis of lesion volume revealed a significant, sustained reduction in generation 3 relative to generation 1 (Fig. 6k, l) , consistent with the observation that resistant Krit1 fl/fl and Ccm2 fl/fl mothers have lower s24-7 levels than susceptible mothers (Fig. 5h) . Conversely, sterile C-section/fostering of resistant Krit1
ECKO and Ccm2
ECKO pups to conventional Swiss Webster foster mothers with high levels of s24-7 (Fig. 5h ) restored CCM susceptibility (Extended Data Fig. 10 ). These findings provide further evidence that qualitative changes in the bacterial microbiome can alter disease course.
Discussion
Designing rational therapies for CCM disease is complicated by the fact that many of the pathogenic events take place within brain endothelial cells of the central nervous system (CNS), where drug delivery is blocked by the blood-brain barrier 34 . The finding that LPS accelerates CCM formation (Fig. 2a-e) although it is unable to cross the bloodbrain barrier 35 suggests that CCM formation is driven by activation of endothelial TLR4 receptors on the luminal, blood side of the bloodbrain barrier (Fig. 6a) . TAK-242 or LPS-RS effectively reduce lesion formation, confirming endothelial TLR4 as a 'druggable' target for CCM disease (Fig. 6b-d, Extended Data Fig. 8 ). Existing TLR4 blocking agents developed for sepsis treatment 36 could potentially be repurposed as therapies for severe human CCM disease. However, such application will first need to address the requirement for chronic therapy, the potential risk of lethal sepsis, and whether anti-TLR4 therapy will affect existing as well as nascent lesions.
Manipulation of gut microbiome-host interactions is a more exciting potential strategy to treat a life-long disease such as CCM. The microbiome has been associated with many human diseases 37 , but specific molecular mechanisms by which it contributes to disease pathogenesis have been difficult to define. Our studies support a central role for the gut microbiome and endothelial responses to GNB in the pathogenesis of CCMs. We find that the bacterial microbiome is the primary source of TLR4 ligand required to stimulate CCM formation in mice, and that small qualitative differences in the gut microbiome may have marked effects on the course of CCM disease in this animal model. Although s24-7 is not found in humans, the association of CCM disease susceptibility with this GNB is particularly interesting because it is associated with disruption of the gut epithelial barrier 38 . Thus, a key step in CCM pathogenesis is predicted to be translocation of bacteria or bacterial LPS from the gut lumen into circulation (Fig. 6a) . Whether similar inflammatory/colitogenic microbiomes also accelerate human CCM disease remains an important question. The clinical course of CCM disease is exceptionally variable, even among individuals with familial CCM disease due to a common KRIT1 mutation 4, 6 . Genetic polymorphisms that alter TLR4 and CD14 expression account for some of this heterogeneity (Fig. 3) , but most of the clinical variability remains unexplained and may reflect the effect of individual microbiomes. Future studies that simultaneously define the genomes and microbiomes of CCM patients will be required to test this intriguing hypothesis and determine whether the microbiome is a viable therapeutic target for this disease.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. ECKO mating pairs were used to test the acute and chronic effects of antibiotic treatment on CCM formation. ABX, antibiotics; G, generation. f-h, Visual and corresponding microCT images of hindbrains from offspring of three generations from one mating pair, representative of three pairs. i, Lesion volume quantification. Red star denotes pup with abscess. j, Relative quantification of neonatal gut bacterial load measured by qPCR of the bacterial 16S rRNA gene. n = 4 per group. k, l, Relative quantification of Bacteroidetes s24-7 (s24-7) load in the neonatal gut measured by qPCR of the s24-7 rRNA gene (two distinct primer sets). n ≥ 8 per group. All scale bars, 1 mm. Error bars shown as s.e.m. or boxplot and significance determined by one-way ANOVA with Holm-Sidak correction for multiple comparisons. * * * * P < 0.0001; * * * P < 0.001; * * P < 0.01; * P < 0.05; NS, P > 0.05.
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University of Pennsylvania mice. The Cdh5(PAC)-Cre
ERT2 transgenic mice (iECre) were a gift from R. H. Adams 39 .
Krit1
fl/fl and Ccm2 fl/fl animals have been previously described 40, 41 . Tlr4
, Ai14 (R26-LSL-RFP), and R26-Cre ERT2 animals [42] [43] [44] [45] were obtained from the Jackson Laboratories. The Slco1c1(BAC)-Cre ERT2 transgenic mice have been previously described 18 . All experimental animals were maintained on a mixed 129/SvJ, C57BL/6J, DBA/2J genetic background unless specifically described. C57BL/6J and timed pregnant Swiss Webster mice were purchased from Charles River Laboratories. Germ-free Swiss Webster mice were purchased from Taconic. Breeding pairs between two and ten months of age were used to generate the neonatal CCM mouse model pups. Mice were housed in a specific pathogen-free facility where cages were changed on a weekly basis; ventilated cages, bedding, food, and acidified water (pH 2.5-3.0) were autoclaved before use, ambient temperature maintained at 23 °C, and 5% Clidox-S was used as a disinfectant. Experimental breeding cages were randomly housed on three different racks in the vivarium, and all cages were kept on automatic 12-h light/dark cycles. The University of Pennsylvania Institutional Animal Care and Use Committee (IACUC) approved all animal protocols, and all procedures were performed in accordance with these protocols.
Centenary Institute mice. A group of the resistant Ccm2
ECKO colony was exported to the Centenary Institute, Sydney, Australia, where the mice were permanently maintained as an inbred colony in a quarantine facility. After several generations, this colony uniformly converted to lesion susceptibility. Cages were changed on a weekly basis; ventilated cages, bedding, food and acidified water (pH 2.5-3.0) were autoclaved before use. Ambient temperature was maintained between 22-26 °C, and 80% ethanol and F10SC (1:125 dilution of the concentrate, a quaternary ammonium compound) were used as disinfectants. Experimental breeding cages were randomly distributed throughout the vivarium, and all cages were kept on 12-h light/dark cycles. The Sydney Local Health District Animal Welfare Committee approved all animal ethics and protocols. All experiments were conducted under the guidelines/regulations of Centenary Institute and the University of Sydney. Gnotobiotic animal husbandry. Germ-free Swiss Webster mice were purchased from Taconic and directly transferred into sterile isolators (Class Biologically Clean Ltd) under the care of the Penn Gnotobiotic Mouse Facility. Food, bedding and water (non-acidified) were autoclaved before transfer into the sterile isolators. Ventilated cages were changed weekly, and all cages in the vivarium were kept under 12-h light/dark cycles. Microbiology testing (aerobic and anaerobic culture, 16S qPCR) was performed every ten days and faecal samples were sent to Charles Rivers Laboratories for pathology testing on a quarterly basis. Further details regarding the sterile C-section fostering can be found below. The University of Pennsylvania Institutional Animal Care and Use Committee (IACUC) approved all animal protocols, and all procedures were performed in accordance with these protocols. Induction of the neonatal CCM mouse model. For all neonatal CCM mouse model experiments, at one day post-birth (P1), pups were intragastrically injected by 30-gauge needle with 40 μ g of 4-hydroxytamoxifen (4OHT, Sigma Aldrich, H7904) dissolved in a 9% ethanol/corn oil (volume/volume) vehicle (50 μ l total volume per injection). This solution was freshly prepared from pre-measured, 4OHT powder for every injection. Before injection, the pup skin was sanitized using ethanol wipes. The P1 time point was defined by checking experimental breeding pairs every evening for new litters. The following morning (P1), pups were injected with 4OHT. All experimental pups were subjected to this induction regimen. For the Tlr4 rescue experiment (Fig. 2) , and all lineage-tracing experiments, an additional dose of 40 μ g 4OHT was intragastrically delivered at P2 (P1+ 2, two total doses). Pups were then harvested as previously described 9 at the specified time points. Histology. Tissue samples were fixed in 4% formaldehyde overnight, dehydrated in 100% ethanol, and embedded in paraffin. 5-μ m-thick sections were used for haematoxylin and eosin (H&E) and immunohistochemistry staining. The following antibodies were used for immunostaining: rat anti-PECAM (1:20, Histo Bio Tech DIA-310), rabbit anti-pMLC2 (1:200, Cell Signaling 3674S), goat anti-KLF4 (1:100, R&D AF3158), and rabbit anti-RFP (1:50, Rockland 600-401-379). Littermate control and experimental animal sections were placed on the same slide and immunostained at the same time under identical conditions. Images were taken at the same time using the same exposure times and colour channels, and were subsequently overlaid using ImageJ. Gram staining. Intra-abdominal abscesses were dissected and triturated in 500 μ l of SOC medium. Drops of the mixture were placed on a microscope slide, briefly exposed to heat, and Gram staining was performed using a kit from Sigma Aldrich (77730) following the manufacturer's protocol. Whole-mount retinal endothelium staining. Eyes from euthanized P17 mice were removed and fixed overnight in cold 4% PFA/PBS solution. The following day, retinas were dissected, cut into petals, and stained with isolectin-B4 conjugated to Alexa488 fluorophore (Thermo Fisher I21411) as previously described 46 . The retinas were then whole-mounted on microscopy slides in a flat, four-petal shape for fluorescence imaging. Bacteroides fragilis abscess model. B. fragilis was purchased directly from the ATCC (strain 25285) and grown in chopped meat glucose (CMG) broth (Anaerobe Systems AS-813) under anaerobic conditions at 37 °C. Autoclaved, degassed caecal contents (ACC) were generated by collecting caecal contents from the colons of euthanized adult mice between 2-8 months of age. Caecal contents were then autoclaved and pulverized in an equal volume of CMG broth. This slurry was filtered through a 70-μ m nylon strainer and degassed overnight in the anaerobic chamber. 1 ml of CMG broth was inoculated with B. fragilis and grown overnight to an optical density of between 0.8 and 1.0. An equal volume of ACC was mixed with the overnight bacterial culture. 100 μ l of this B. fragilis-ACC mixture was injected intraperitoneally into five-day-old pups with a 31-gauge needle. Control littermates were simultaneously injected intraperitoneally with 100 μ l of ACC alone. Pups were harvested at P17. Spleen weight was measured immediately after dissection, and all tissue was subsequently processed as described above. Intravenous LPS, peptidoglycan, poly(I:C), IL-1β and TNFα injections. LPS from E. coli O127:B8 was purchased from Sigma (L3129) and administered to the low-lesion-penetrance, resistant Ccm2
ECKO neonatal CCM disease model. At P5, a 3 μ g dose of LPS dissolved in sterile PBS was administered retro-orbitally in a total 30 μ l volume by 31-gauge needle. At P10, a 5 μ g dose of LPS was administered retro-orbitally in a total 50 μ l volume by 31-gauge needle. Control animals were identically injected with PBS alone. Pups were euthanized and brains dissected at specified time points. Peptidoglycan from Bacillus subtilis (a Gram-positive gut commensal) was purchased from Invivogen (tlrl-pgnb3) and administered to the resistant Ccm2
ECKO neonatal CCM disease model under identical conditions as the LPS experiments. Poly(I:C) was purchased from Invivogen (tlrl-picw) and administered to the resistant Ccm2
ECKO neonatal CCM disease model under identical conditions as the LPS experiments.
Mouse IL-1β was purchased from Genscript (Z02988) and administered to the resistant Ccm2 ECKO neonatal CCM disease model. At P5, a 5 ng dose of IL-1β dissolved in sterile PBS was administered retro-orbitally in a total 30 μ l volume by 31-gauge needle. At P10, an 8-ng dose of IL-1β was administered retro-orbitally in a total 50 μ l volume by 31-gauge needle. Control animals were identically injected with PBS alone. Pups were euthanized and brains dissected at specified time points. Mouse TNFα was purchased from Genscript (Z02918) and administered to the resistant Ccm2
ECKO neonatal CCM disease model under identical conditions as the IL-1β experiments. Contrast-enhanced microCT. For all experiments using microCT quantification of CCM lesion volume, brains were harvested and immediately placed in 4% PFA/ PBS fixative. Brains remained in fixative until staining with non-destructive, iodine contrast and subsequent microCT imaging performed as previously described 47 . All tissue processing, imaging and volume quantification were performed in a blinded manner by investigators at the University of Chicago without any knowledge of experimental details.
We blinded samples at three distinct points in the analysis. First, neonatal CCM model pups were injected with 4OHT without knowledge of genotypes. Second, hindbrains from genotyped animals were given randomized, de-identified labels to provide for blinded microCT scanning by an independent operator. Third, randomized microCT image stacks were analysed in a blinded manner by individuals not involved in any prior experimental steps. Immune cell isolation from neonatal brain. Mice were anaesthetized with Avertin and underwent intra-cardic perfusion with 10 ml of cold PBS. The brain was separated from the brainstem, and the cerebellum was separated from the remaining brain and processed in parallel. The tissue was minced with scissors, placed in digestion buffer (RPMI, 20 mM HEPES, 10% FCS, 1 mM CaCl 2 , 1 mM MgCl 2 , 0.05 mg ml −1 Liberase (Sigma), 0.02 mg ml −1 DNase I (Sigma)), and incubated for 40 min at 37 °C with shaking at 200 r.p.m. The mixture was passed through a 100-μ m strainer and washed with FACS buffer (PBS, 1% FBS). Cells were resuspended in 4 ml of 40% Percoll (GE Healthcare) and overlaid on 4 ml of 67% Percoll. Gradients were centrifuged at 400g for 20 min at 4 °C and cells at the interface were collected, washed with 10 ml of FACS buffer, and stained for flow cytometric analysis. Haematopoietic cell isolation from neonatal whole blood, spleen and subsequent FACs analysis. Neonatal P10 mice were anaesthetized with Avertin and underwent intracardiac puncture/blood draw using a 27-gauge needle/syringe coated with 0.5 M EDTA, pH 8.0 immediately before use. Cells were pelleted by centrifugation at 300g for 5 min at 4 °C. Serum was removed and red blood cells were lysed using ACK lysis buffer. Spleens were dissected in parallel, handhomogenized using a mini-pestle and red blood cells were lysed using ACK lysis buffer. Cells from both sets of tissues were passed through a 70-μ m cell-strainer, pelleted and resuspended in FACS buffer (PBS, 2% FBS, 0.1% NaN 3 ) for immunostaining and subsequent FACS analysis.
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Immune cell staining and flow cytometry analysis. Cells were isolated from the indicated tissues. Single-cell suspensions were stained with CD16/32 and with indicated fluorochrome-conjugated antibodies. Live/Dead Fixable Violet Cell Stain Kit (Invitrogen) was used to exclude non-viable cells. Multi-laser, flow cytometry analysis procedures were performed at the University of Pennsylvania Flow Cytometry and Cell Sorting Facility using BD LSRII cell analysers running FACSDiva software (BD Biosciences). Two-laser, flow cytometry analyses were performed at the University of Pennsylvania iPS Cell Core using BD Accuri C6 instruments. FlowJo software (v.10 TreeStar) was used for data analysis and graphics rendering. At the specified time points, cerebellar endothelial cells were isolated through enzymatic digestion followed by separation using magnetic-activated cell sorting by anti-CD31-conjugated magnetic beads (MACS MS system, Miltenyl Biotec), as previously described 9 . Lung endothelial cells were isolated through enzymatic digestion, as previously described, followed by separation using anti-CD31-conjugated magnetic beads and the MACS MS system 48 . Isolated endothelial cells were pelleted and total RNA was extracted using the RNeasy Micro kit (Qiagen 74004). For qPCR analysis, cDNA was synthesized from 300 ng to 500 ng total RNA using the SuperScript VILO cDNA Synthesis Kit and Master Mix (Thermo Fisher 11755050). Real-time PCR was performed with Power SYBR Green PCR Master Mix (Thermo Fisher 4368577) using the primers listed (all mouse): Gapdh forward: 5′ -AAATGGTGAAGGTCGGTGTGAACG-3′ ; Gapdh reverse: 5′ -ATCTCCACTTTGCCACTGC-3′ ; Klf2 forward: 5′ -CGCCTCGGGTTCAT TTC-3′ ; Klf2 reverse: 5′ -AGCCTATCTTGCCGTCCTTT-3′ ; Klf4 forward: 5′ -GTGCCCCGACTAACCGTTG-3′ ; Klf4 reverse: 5′ -GTCGTTGAACTCCTC GGTCT-3′ ; Krit1 forward: 5′ -CCGACCTTCTCCCCTTGAAC-3′ ; Krit1 reverse: 5′ -TCTTCCACAACGCTGCTCAT-3′ ; Il1b forward: 5′ -GCAACTGTTCCT GAACTCAACT-3′ ; Il1b reverse: 5′ -ATCTTTTGGGGTCCGTCAACT-3′ ; Sele forward: 5′ -ATGCCTCGCGCTTTCTCTC-3′ ; Sele reverse: 5′ -GTAGTCCCGC TGACAGTATGC-3′ ; Tlr4 forward: 5′ -ACTGGGGACAATTCACTAGAGC-3′ ; Tlr4 reverse: 5′ -GAGGCCAATTTTGTCTCCACA-3′ . Identification of human CCM associated single nucleotide polymorphisms. As part of the Brain Vascular Malformation Consortium (BVMC) CCM study (Project 1), a large cohort of familial CCM individuals with identical KRIT1(Q455X) mutations were enrolled between 2009-2014 at the University of New Mexico. All study protocols were approved by the Institutional Review Boards at the University of New Mexico and University of California San Francisco (UCSF) and all procedures were performed in accordance with these protocols. Prior to participation in the study, written informed consent was obtained from every patient and properly documented by UNM investigators.
At study enrollment, participants received a neurological examination and 3T MRI imaging using a volume T1 acquisition (MPRAGE, 1-mm slice reconstruction) and axial TSE T2, T2 gradient recall, susceptibility-weighted, and FLAIR sequences. Lesion counting by the neuroradiologist was based on concurrent evaluation of axial susceptibility-weighted imaging with 1.5-mm reconstructed images and axial T2 gradient echo 3-mm images.
Participants also provided blood or saliva samples for genetic studies. Genomic DNA was extracted using standard protocols. De-identified samples were normalized, plated on 96-well plates, and genotyped at the UCSF Genomics Core Facility using the Affymetrix Axiom Genome-wide LAT1 Human Array. Affymetrix Genotyping Console (GTC) 4.1 Software package was used to generate quality control metrics and genotype calls. All samples had genotyping call rates of ≥ 97% and were further checked for sample mix-ups (sex check, Mendelian errors and cryptic relatedness), resulting in 188 samples for genetic analysis.
21 candidate genes were further examined in the TLR4 and MEKK3-KLF2/4 signalling pathways (TLR4, CD14, MD-2, LBP, MYD88, TICAM1, TIRAP, TRAF1-6, MAP3K3, MEK5, ERK5, MEF2C, KLF2, KLF4, ADAMTS4, ADAMTS5) including 467 SNPs within 20 kb upstream or downstream of each gene locus using UCSC Genome Browser coordinates (GRCh37/hg19). Because total lesion counts are highly right-skewed, raw counts were log-transformed and analysis was performed on residuals (adjusted for age at enrollment and sex). To identify genotypes associated with log-transformed residual counts, linear regression analysis was implemented using QFAM family-based association tests for quantitative traits (PLINK v1.07 software), with stringent multiple testing correction (Bonferroni correction for the number of SNPs tested within each gene) given that some SNPs on the Affymetrix array were in linkage disequilibrium with each other, that is, statistically correlated with R 2 > 0.8. Characterization of human cis-eQTLs. The Fehrmann dataset used for eQTL lookups consisted of peripheral blood samples from the UK and the Netherlands 49, 50 . Samples were genotyped with Illumina HumanHap300, HumanHap370 or 610 Quad platforms. Genotypes were input by Impute v2 (ref. 51) using the GIANT 1000G p1v3 integrated call set for all ancestries as a reference 52 . Gene expression levels were measured by Illumina HT12v3 arrays. Gene expression pre-processing involved quantile normalization, log 2 transformation, probe centring and scaling, population stratification correction (first four genetic multi-dimensional scaling components were removed from gene expression data) and correction for unknown confounders (first 20 gene expression principal components not associated with genetic variants were removed from gene expression data). Identification of potential sample mix-ups was conducted by MixupMapper 21 and finally 1,227 samples remained. All pre-processing steps were performed with the QTL mapping pipeline v1.2.4D (https://github.com/molgenis/ systemsgenetics/tree/master/eqtl-mapping-pipeline -downloading-the-software).
These results are corroborated by an independently conducted GTEX Consortium study (http://www.gtexportal.org/home/snp/rs10759930 and http://www.gtexportal.org/home/snp/rs778587). TAK-242 and LPS-RS administration. TAK-242 was purchased from EMD Millipore (614316) and administered to the neonatal CCM disease model. Five, seven and nine days after birth, a 60-μ g dose of TAK-242 was dissolved in DMSO/ sterile intralipid (Sigma, I141) vehicle and administered retro-orbitally in a total volume of 30 μ l. Control animals were identically injected with sterile DMSO/ intralipid vehicle alone. Pups were euthanized and brains dissected 10 days after birth.
LPS-RS ultrapure was purchased from Invivogen (tlrl-prslps) and administered to the neonatal CCM disease model. Starting at P5, a 20 μ g dose dissolved in sterile PBS was administered retro-orbitally in a total volume of 30 μ l every 24 h. Control animals were identically injected with sterile PBS alone. Pups were euthanized and brains dissected 10 days after birth. Transgenerational antibiotic administration. Experimental breeding pairs of mice, yielding susceptible neonatal CCM pups, were identified by induction of a neonatal CCM litter and evaluation of lesion burden. These breeding pairs then underwent timed matings and at E14.5, both male and female adult mice received antibiotic-laced drinking water mixed with 40 g l −1 of sucralose and red food colouring. Antibiotic water was replaced daily. The following antibiotics were mixed with 0.22-μ m-filtered water: penicillin (500 mg l ), streptomycin (500 mg l −1 ), metronidazole (1 g l -1 ) and vancomycin (1 g l −1 ). Antibiotics were purchased from the Hospital of the University of Pennsylvania pharmacy. The neonatal CCM model was induced as described above. At P10, pups were euthanized and antibiotic water switched to normal drinking water. Experimental breeding pairs were then mated to obtain third generation, postantibiotic pups. Vancomycin mono-antibiotic administration. Co-housed, susceptible Krit1 fl/fl females underwent evening-morning timed matings with a single susceptible Krit1 ECKO male. Upon detection of a plug in the morning, the females were subsequently separated into singly-housed cages. At E14.5, female mice were received either vancomycin (1 g l
)-laced or untreated (vehicle) sterile-filtered drinking water, changed daily. The drinking water was further mixed with 40 g l −1 sucralose and red food colouring. Pups were harvested at P11. Bacterial DNA extraction from neonatal mouse guts and bacterial ribosomal DNA qPCR. The entire neonatal gut was dissected, snap-frozen on dry ice, and stored at − 80 °C. The QIAamp DNA Stool Mini Kit (Qiagen 51504 or 51604) was used to extract bacterial DNA from the neonatal gut. Before commencing the standard Qiagen protocol, the frozen gut was mixed in the included stool lysis buffer and homogenized with a 5 mm stainless steel bead in a TissueLyser LT (Qiagen 69980) at 50 Hz for 10 min at 4 °C. Concentration of the extracted DNA was equalized and 16 ng of DNA was used per qPCR reaction with universal bacterial 16S rRNA gene primers 53 , two different sets of previously characterized Bacteroidetes s24-7 primers 54, 55 , and Firmicutes primers 56 . Universal 16S rRNA forward: 5′ -ACTGAGAYACGGYCCA-3′ ; universal 16S rRNA reverse: 5′ -TTACCGCGGCTGCTGGC-3′ ; Bacteroidetes s24-7 rRNA set 1 forward: 5′ -GGAGAGTACCCGGAGAAAAAGC-3′ ; Bacteroidetes s24-7 rRNA set 1 reverse: 5′ -TTCCGCATACTTCTCGCCCA-3′ ; Bacteroidetes s24-7 rRNA set 2 forward: 5′ -CCAGCAGCCGCGGTAATA-3′ ; Bacteroidetes s24-7 rRNA set 2 reverse: 5′ -CGCATTCCGCATACTTCTC-3′ ; Firmicutes rRNA forward: 5′ -TGAAACTYAAAGGAATTGACG-3′ ; Firmicutes rRNA reverse: 5′ -ACCATGC ACCACCTGTC-3′ .
Sterile C-section and fostering to conventional Swiss Webster recipient females. Evening-morning timed matings to generate donor susceptible or resistant females yielding Krit1 ECKO or Ccm2 ECKO pups were performed and timed pregnant Swiss Webster females (Charles River 024) served as foster mothers. To prevent delivery of the pups, at E16.5, donor females were injected subcutaneously with 100 μ l of a 15 μ g ml −1 solution of medroxyprogesterone (Sigma Aldrich, M1629) dissolved in DMSO. The morning of E19.5, the donor mother was euthanized by cervical dislocation and submerged in a warm sterile solution of 1% VirkonS/PBS (weight/ volume) for one minute. The uterus was then dissected in a sterile laminar flow hood, submerged in a warm sterile solution of 1% VirkonS/PBS for one minute and quickly rinsed with warm sterile PBS. Pups were then removed from the uterus and fostered to the Swiss Webster recipient female. The following morning, induction of the neonatal CCM model was performed as described above. Sterile C-section and fostering to germ-free Swiss Webster recipient females. Timed matings were performed using germ-free Swiss Webster mice housed in sterile isolators under care of the University of Pennsylvania Gnotobiotic Mouse Facility. Simultaneous evening-morning timed matings were also performed using co-housed, susceptible Krit1 fl/fl females and Krit1 ECKO males previously characterized to yield CCM-susceptible pups. Medroxyprogesterone was administered to donor females and the sterile C-section was performed at E19.5 as described in the previous section. The intact uterus was passed through a J-tube filled with warm 1% VirkonS/PBS that was hermetically sealed to the sterile isolator. Pups were dissected from the uterus inside the sterile isolator and fostered to the recipient germ-free Swiss Webster mother. Approximately one week later, faecal samples were collected for microbiology testing. Germ-free status was further confirmed by 16S qPCR of bacterial DNA isolated from maternal faeces and neonatal guts. Collection of maternal CCM mouse faeces. Fresh faecal pellets were collected from experimental females yielding susceptible or resistant pups one day after harvesting the pups to determine phenotypic severity. Collection was performed between 16:00 and 18:00, pellets were immediately snap-frozen on dry ice, and stored at − 80 °C. Extraction and library preparation of bacterial DNA for 16S rRNA gene sequencing. DNA was extracted from stool samples using the Power Soil htp kit (Mo Bio Laboratories) following the manufacturer's protocol. Library preparation was performed by using previously described barcoded primers targeting the V1/ V2 region of the 16S rRNA gene 57 . PCR reactions were performed in quadruplicate using AccuPrime Taq DNA Polymerase High Fidelity (Invitrogen). Each PCR reaction consisted of 0.4 μ M primers, 1× AccuPrime Buffer II, 1 U Taq, and 25 ng DNA. PCRs were run using the following parameters: 95 °C for 5 min; 20 cycles of 95 °C for 30 s, 56 °C for 30 s, and 72 °C for 90 s; and 72 °C for 8 min. Quadruplicate PCR reactions were pooled and products were purified using AMPureXP beads (Beckman-Coulter). Equimolar amounts from each sample were pooled to produce the final library. Positive and negative controls were carried through the amplification, purification and pooling procedures. Negative controls were used to assess reagent contamination and consisted of extraction blanks and DNA-free water. Positive controls were used to assess amplification and sequencing quality and consisted of gBlock DNA (Integrated DNA Technologies) containing non-bacterial 16S rRNA gene sequences flanked by bacterial V1 and V2 primer binding sites. Paired-end 2 × 250 bp sequence reads were obtained from the MiSeq (Illumina) using the 500 cycle v2 kit (Illumina). Analysis of 16S sequencing. Sequence data were processed using QIIME version 1.9.1 (ref. 58) . Read pairs were joined to form a complete V1/V2 amplicon sequence. Resulting sequences were quality filtered and demultiplexed. Operational taxonomic units (OTUs) were selected by clustering reads at 97% sequence similarity 59 . Taxonomy was assigned to each OTU with a 90% sequence similarity threshold using the Greengenes reference database 60 . A phylogenetic tree was inferred from the OTU data using FastTree 61 . The phylogenetic tree was then used to calculate weighted and unweighted UniFrac distances between each pair of samples in the study 62, 63 . Microbiome compositional differences were visualized using principle coordinates analysis (PCoA). Community-level differences between mice genetic background as well as disease susceptibility groups were assessed using a PERMANOVA test 64 of weighted and unweighted UniFrac distances. To assess significance in the PERMANOVA test, each cage was randomly re-assigned to groups 9,999 times. Differential abundance was assessed for taxa present in at least 80% of the samples, using generalized linear mixed-effects models. For tests of taxon abundance, the cage was modelled as a random effect, as previous research has established that the faecal microbiota of mice are correlated within cages 65 . The P values were corrected for multiple testing using Benjamini-Hochberg method. Statistics. Sample sizes were estimated on the basis of our previous experience with the neonatal CCM model and lesion volume quantification by microCT 9 . Using 40 historically collected, susceptible Krit1 ECKO and Ccm2 ECKO P10 brains, we calculated a sample standard deviation of 0.250 mm 3 . Between Krit1 ECKO and Ccm2 ECKO genotypes, an F-test to compare variances confirmed no significant difference (P = 0.340). Thus, for a two-group comparison of lesion volumes, each sample group requires seven animals for a desired statistical power of 95% (β = 0.05), and a conventional significance threshold of 5% (α = 0.05) assuming an effect size of 50% (0.5) and equal standard deviations between sample groups. These predictive calculations were corroborated by our recent publication in which larger effect sizes (> 90%) were found to be statistically significant with four to five samples per group 9 . All experimental and control animals were littermates and none were excluded from analysis at the time of harvest. Experimental animals were lost or excluded at two pre-defined points: (i) failure to properly inject 4OHT and observation of significant leakage; (ii) death before P10 because of injection or chaos. Given the early time points, no attempt was made to distinguish or segregate results based on neonatal genders. P values were calculated as indicated in figure legends using an unpaired, two-tailed Student's t-test; one-way ANOVA with multiple comparison corrections (Holm-Sidak or Bonferroni); PERMANOVA; or linear mixed effects modelling. As indicated in the figure legends, the standard error of the mean (s.e.m.), 95% confidence interval, or boxplot is shown. Data availability. All relevant data are available from the authors upon reasonable request.
Extended Data Figure 1 | CCM formation in resistant Ccm2
ECKO animals is stimulated by abscess formation and LPS. a, Resistance to CCM formation is maintained in a C57BL/6J strain background. Ccm2 ECKO (iECre;Ccm2 fl/fl ) animals were backcrossed seven generations onto a C57BL/6J background and gene deletion was induced at P1 with visual hindbrain assessment at P10. n = 7. Scale bars, 1 mm. b, Retinal CCM formation is stimulated by GNB infection. Retinas of P17 resistant Ccm2 ECKO littermates are shown. The sample shown below is from an animal that developed the spontaneous Gram-negative abscess shown in Fig. 1c. Scale bars, 500 μ m. c, d , Administration of LPS does not drive CCM formation in Cre-negative neonatal mice. LPS was administered intravenously to Ccm2 fl/fl and Ccm2 ECKO littermates as shown in Fig. 1g , and hindbrains assessed at P17 visually (c) and histologically (H&E staining; d). n ≥ 3 per group. Scale bars, 1 mm (c) and 100 μ m (d). e, LPS induces myosin light chain activation in CCM-deficient brain endothelial cells. Phospho-myosin light chain (pMLC) and PECAM staining of hindbrains from P5 LPS-or vehicle-injected resistant Ccm2 ECKO littermates. Dotted lines trace the Purkinje cell layer. n ≥ 4 per group. Scale bars, 50 μ m. f, Tlr4 expression does not differ between CCM susceptible and resistant animals. Tlr4 expression was measured using qPCR in cerebellar endothelial cells isolated from the indicated animals at P10. Error bars shown as s.e.m. and significance determined by unpaired, two-tailed Student's t-test. n.s., P > 0.05.
